Clay Siegall: The Brain Behind Cancer-Based Genetic Research

In January 2013, Mirna Therapeutics appointed the chairperson and present CEO of Seattle Genetics, Clay Siegall to its long list of Board of Directors as an outside director. The rich cancer research history that Clay possesses was seen as the main driving force towards his appointment by Mirna Therapeutics CEO, DR. Paul Lammers.
Though both of these companies are thousands of miles apart, both of them share the fact that they deal with the overall study of genes, towards the search for a cancer treatment. Mirna Therapeutics primarily focuses on microRNA Therapeutics, while Seattle Genetics mainly deals with the study of genes in relation to the development, growth, and treatment of cancer. Mirna Therapeutics is located in Austin, Texas, while Seattle Genetics is based in Seattle, Washington.
Since its inception in 1997, Seattle Genetics has successfully created antibody-based therapies, directed towards the treatment of cancer. The company focuses on developing innovative and productive monoclonal antibody-related therapies for the treatment of cancers. With over a decade in the industry, Seattle Genetics brags itself as the world leader in the production of antibody-drug conjugates (ADCs), a technology designed to create monoclonal antibodies, and increase their chances of killing cancer cells.
On the other hand, Mirna Therapeutics is a biopharmaceutical company that deals with the development of oncology-based microRNA genes towards the treatment of liver cancer. The company which was founded in 2007 brags as been the first company to develop an oncology-based MRX34 gene (a microRNA mimic) which experts believe holds the key towards the treatment and control of cancer.
Clay Siegall attended the University of Maryland where he earned his Bachelor of Science in Science in Zoology. His desire to succeed in life and offer second chances to cancer patients, made him pursue a Ph.D. in Genetics, at the George Washington University. After successfully completing the program and graduating, Clay worked for the National Institutes of Health, the National Cancer Institute as well as the Bristol-Myers Squibb Pharmaceutical Research Institute before finally co-founding the Seattle Genetics with Todd E. Simpson back in 1997. Clay is also a board member of the Ultragenyx Pharmaceutical, a position he has held since January 2014.

Read below to learn more:

Clay Siegall and Seattle Genetics